In summary, our results demonstrate that flubendazole enhances the inhibitory effect of paclitaxel via the HIF1α/PI3K/AKT signaling pathways, offering valuable insights for finding more novel combination therapies for BC in the future. Here, AKT1 is linked to breast cancer.